InspireMD Inc. (NASDAQ:NSPR) Q2 2023 Results Conference Call August 8, 2023 8:30 AM ET
Company Participants
Glenn Garmont - IR
Marvin Slosman - President, CEO and Director
Amir Kohen - Interim CFO, Secretary and Treasurer
Conference Call Participants
Adam Maeder - Piper Sandler
Benjamin Haynor - Alliance Global Partners
Operator
Good morning, and welcome to the InspireMD Second Quarter 2023 Earnings Call. Currently all participants are in a listen-only mode. [Operator Instructions] After today’s presentation there will be opportunity to ask questions. [Operator Instruction] Please note, this conference is being recorded.
I will now turn the conference over to Glenn Garmont with LifeSci Advisors. Thank you. You may begin.
Glenn Garmont
Thank you, operator. Good morning, everyone. Thank you for joining us for the InspireMD second quarter 2023 financial results and corporate update conference call. Joining us today from InspireMD are Marvin Slosman, Chief Executive Officer.
During this call, management will be making forward-looking statements, not historical facts and are based upon management's current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. They involve risks and uncertainties that may cause actual results to differ materially from those expressed in the forward-looking statements. For more information about these risks, please refer to the risk factors described in InspireMD's most recently filed periodic reports on Form 10-K and Form 10-Q filed with the U.S. Securities and Exchange Commission and InspireMD's press release that accompanies this call, particularly the cautionary statements made in it.
The call contains time-sensitive information that is accurate only as of today, August 8, 2023, except as required by law, InspireMD disclaims any obligation to publicly update or revise any information to reflect events or circumstances that occur after this call.
It's now my pleasure to turn the call over to Marvin Slosman, Chief Executive Officer. Marvin, please go ahead.
Marvin Slosman
Thank you, Glenn, and thanks to everyone for joining our call this morning. I'm pleased to share that the second quarter of 2023 proved to be a transformational time for our company as we advanced our mission to lead the carotid revascularization market with next-generation solutions built on the foundation of our CGuard carotid stent platform.
The second quarter produced our highest revenue to date for our CGuard carotid stent system as well as the successful financing of up to $113.6 million in new capital. Specific to our financials, we generated total revenue of $1.649 million, our highest CGuard quarterly revenue to date, representing growth of nearly 10% over the second quarter of 2022 and sequential growth of 33% over the first quarter of 2023.